Searchable abstracts of presentations at key conferences on calcified tissues

ba0003pp304 | Osteoporosis: treatment | ECTS2014

Activin decoy receptor (IIA) ameliorates immobilisation induced loss of bone and muscle mass in mice

Lodberg Andreas , Thomsen Jesper Skovhus , Bruel Annemarie

Activin is a known physiologic regulator of bone metabolism. Ovariectomy-induced osteopenia has been shown to be attenuated by injection of the activin type IIA decoy receptor (ActRIIA-Fc). However, immobilization-induced osteopenia is driven by different pathways than ovariectomy-induced osteopenia, and the role of activin in immobilization-induced osteopenia has not yet been elucidated.The purpose of the study was to investigate the possible attenuatio...

ba0003lb1 | (1) | ECTS2014

Endochrondral ossification, mesenchymal stem cell and Wnt pathway specific loci predict differential skeletal effects in high bone mass

Gregson Celia , Kemp John , Marshall Mhairi , Smith George Davey , Brown Matthew , Duncan Emma , Tobias Jon

Extreme high bone mass (HBM) may be monogenic (e.g. LRP5 mutations) or polygenic, due to variants in the same genes determining bone mineral density (BMD) as found in the general population. We aimed to determine how variation in established BMD loci, in different functional pathways, explains the HBM phenotype.241 unexplained HBM cases (lumbar spine(LS)1+total hip(TH) Z-scoresā‰„+4.4) were recruited from 15 UK centres, by screening...

ba0005p20 | Biochemical testing | ECTS2016

Frozen for 7 years: How long can bones be stored prior to biomechanical testing?

Varela Aurore , Smith Susan

Biomechanical strength testing of bones, considered a key component in bone quality assessment, is a critical end-point in the evaluation of safety and efficacy of test compounds in preclinical studies. Bones are usually preserved frozen and tested within a few months following harvesting. They can also be stored for longer periods and only tested when additional information is required. The objective of this study was to evaluate if differences in biomechanics data between di...

ba0005p75 | Bone development/growth and fracture repair | ECTS2016

Increased periosteal expansion, Osterix expression and osteogenic potential upon bone injury during perturbed PI3K signaling

Walia Bhavita , Scanlon Vanessa , Yu Jungeun , Maye Peter , Drissi Hicham , Sanjay Archana

Periosteum contains mesenchymal progenitors and is essential for fracture healing. Signaling mechanisms governing periosteal reaction to injury remain largely unidentified. We previously investigated how PI3 kinase signaling affects the skeletal system using CblYF/YF knock-in (YF) mice wherein PI3K signaling is perturbed by abolition of interaction between Cbl, an E3 ubiquitin-ligase/adaptor protein, and p85 subunit of PI3K. YF mice displayed increased bone volume u...

ba0005p363 | Osteoporosis: pathophysiology and epidemiology | ECTS2016

Lower FRAX scores but similar femoral neck aBMD in UK dwelling postmenopausal South Asian women as compared with same age Caucasian women

Darling Andrea L , Hart Kathryn H , Lanham-New Susan A

It is unclear as to whether western dwelling South Asian (SA) postmenopausal women have a different fracture risk to that of the native Caucasian (C) population. Moreover, the WHO Fracture Risk Assessment Tool (FRAX) has not been used previously to compare predicted risk of fractures in western dwelling South Asian women with same-age Caucasian women. This analysis used data from n=35 SA [mean (S.D.) age=59 (6) years] and n=136 C [mean (...

ba0006p068 | (1) | ICCBH2017

Craniosynostosis can occur in children with nutritional rickets

Forestier-Zhang L , Arundel P , Cross R Gilbey , Mughal M Z , Offiah A C , Cheung M S

Background: Severe vitamin D deficiency (VDD), is a common disorder, which has complications including rickets, hypocalcaemia, hypotonia, delayed development and cardiomyopathy. Although nutritional rickets associated craniosynostosis has been reported, there is little awareness of this or knowledge about its clinical course or severity. We present five cases of late onset craniosynostosis in association with nutritional rickets.Clinical presentation: Th...

ba0007p74 | (1) | ICCBH2019

Burosumab can improve pain and quality of life for children with X-linked hypophosphataemia and their families: a London centre's experience

Gilbey-Cross Robyn , Sandy Jessica L , Morris Mavali , Cocca Alessandra , Sakka Sophia D , Massey Jill , Cheung Moira S

Objectives: Burosumab, a monoclonal antibody that therapeutically targets the underlying elevated levels of fibroblast growth factor 23 (FGF23) in X-linked hypophosphatemia (XLH), is now available to children out of trial conditions. Our objective was to describe the effect of burosumab on quality of life, functionality and pain in a clinical setting.Methods: Questionnaire tools were completed at baseline, 6 and 9 months for 9 children with XLH starting ...

ba0007p120 | (1) | ICCBH2019

Mutational and phenotypic spectra in 137 Russian patients with inherited forms of rickets

Kulikova Kristina , Kolodkina Anna , Vasiliev Evgeny , Petrov Vasiliy , Tiulpakov Anatoly

Background: Inherited forms of rickets are metabolic bone diseases developing as a result of inadequate mineralization of a growing bone due to disruption of calcium, phosphorus and/or vitamin D metabolism. Diverse phenotypic presentation and aetiology of these disorders pose difficulties for the diagnosis and management.Objective and hypotheses: The aim of this study was to perform molecular diagnostics and clinically characterize 137 patients with here...

ba0007p138 | (1) | ICCBH2019

How early is early enough – Bisphosphonate treatment in Osteogenesis imperfecta

Hoyer-Kuhn Heike , Heistermann Johanna , Schonau Eckhard , Rehberg Mirko , Semler Oliver

Objective: Osteogenesis imperfecta is characterized by hereditary skeletal fragility. Bisphosphonates are the first line medical treatment in moderate and severe OI types III/IV. There is no consensus regarding treatment beginning and treatment regimen in the first years. Objective of the presented project was the evaluation of the therapeutic effect of 1 year of bisphosphonate treatment (BP; neridronate i.v. 2 mg/kg body weight every 3 months) on vertebral shape and mobility ...

ba0001pp8 | Clinical case posters | ECTS2013

Phenotypic change in a patient with hypophosphatasia with the onset of renal failure

Cundy Tim , Michigami Toshimi , Tachikawa Kanako , Dray Michael , Collins John

Hypophosphatasia is a recessively inherited disorder with a wide phenotypic manifestation ranging from lethality in neonates to asymptomatic in adults. The severity of the phenotype is largely determined by the nature of the ALPL mutations. We describe a previously asymptomatic adult whose phenotype dramatically changed after he developed renal failure. A 50-year-old man was diagnosed with IgA nephropathy. At age 52 (eGFR 50 ml/min) he suffered his first metatarsal fr...